{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mixed+Tumor%2C+Mullerian", "query": { "condition": "Mixed Tumor, Mullerian" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 99, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mixed+Tumor%2C+Mullerian&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T13:15:48.843Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05902988", "title": "A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "High Grade Serous Adenocarcinoma of Ovary", "Squamous Non-small-cell Lung Cancer", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Ovarian Carcinosarcoma", "Uterine Carcinosarcoma", "Uterine Serous Carcinoma", "Endometrium Cancer", "Chromosomal Instability" ], "interventions": [ { "name": "VLS-1488", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Volastra Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2023-10-18", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-07-23T13:15:48.843Z", "location_count": 14, "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05902988" }, { "nct_id": "NCT03686124", "title": "ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Cancer", "Recurrent Cancer", "Solid Tumor, Adult", "Cancer" ], "interventions": [ { "name": "IMA203 Product", "type": "BIOLOGICAL" }, { "name": "IMA203 product- flat dose", "type": "BIOLOGICAL" }, { "name": "IMA203CD8 Product", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "IMADetect®", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Immatics US, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 375, "start_date": "2019-05-14", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-07-23T13:15:48.843Z", "location_count": 13, "location_summary": "Stanford, California • Aurora, Colorado • Miami, Florida + 8 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03686124" }, { "nct_id": "NCT00659360", "title": "AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Fibrosarcoma", "Adult Leiomyosarcoma", "Adult Liposarcoma", "Adult Malignant Fibrous Histiocytoma", "Adult Rhabdomyosarcoma", "Dermatofibrosarcoma Protuberans", "Endometrial Stromal Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Uterine Sarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage III Uterine Sarcoma", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Uterine Sarcoma", "Uterine Carcinosarcoma", "Uterine Leiomyosarcoma" ], "interventions": [ { "name": "saracatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2008-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2018-06-29", "last_synced_at": "2026-07-23T13:15:48.843Z", "location_count": 1, "location_summary": "Rockledge, Pennsylvania", "locations": [ { "city": "Rockledge", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00659360" }, { "nct_id": "NCT03120624", "title": "VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Endometrial Carcinoma", "Recurrent Endometrial Adenocarcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Endometrial Mixed Cell Adenocarcinoma", "Recurrent Endometrial Serous Adenocarcinoma", "Recurrent Endometrial Undifferentiated Carcinoma", "Recurrent Uterine Corpus Carcinosarcoma", "Stage IV Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorine F 18 Tetrafluoroborate", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Technetium Tc-99m Sodium Pertechnetate", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 34, "start_date": "2017-09-15", "completion_date": "2028-01-01", "has_results": true, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-07-23T13:15:48.843Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03120624" }, { "nct_id": "NCT00003718", "title": "Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Ovarian Cancer", "Sarcoma" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Herbert Irving Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "1998-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-07-23T13:15:48.843Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003718" }, { "nct_id": "NCT00421889", "title": "A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Bladder Cancer" ], "interventions": [ { "name": "belinostat", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Valerio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2005-08", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2015-07-28", "last_synced_at": "2026-07-23T13:15:48.843Z", "location_count": 7, "location_summary": "Newport Beach, California • Orlando, Florida • Covington, Louisiana + 4 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Covington", "state": "Louisiana" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00421889" }, { "nct_id": "NCT00954174", "title": "Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mixed Mesodermal (Mullerian) Tumor", "Ovarian Carcinosarcoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Stage I Ovarian Cancer AJCC v6 and v7", "Stage IA Fallopian Tube Cancer AJCC v6 and v7", "Stage IA Ovarian Cancer AJCC v6 and v7", "Stage IA Uterine Sarcoma AJCC v7", "Stage IB Fallopian Tube Cancer AJCC v6 and v7", "Stage IB Ovarian Cancer AJCC v6 and v7", "Stage IB Uterine Sarcoma AJCC v7", "Stage IC Fallopian Tube Cancer AJCC v6 and v7", "Stage IC Ovarian Cancer AJCC v6 and v7", "Stage IC Uterine Sarcoma AJCC v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIA Uterine Sarcoma AJCC v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIB Uterine Sarcoma AJCC v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIA Uterine Sarcoma AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIB Uterine Sarcoma AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IIIC Uterine Sarcoma AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7", "Stage IVA Uterine Sarcoma AJCC v7", "Stage IVB Uterine Sarcoma AJCC v7", "Uterine Carcinosarcoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 637, "start_date": "2009-08-17", "completion_date": null, "has_results": true, "last_update_posted_date": "2021-09-30", "last_synced_at": "2026-07-23T13:15:48.843Z", "location_count": 532, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 346 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00954174" }, { "nct_id": "NCT05256225", "title": "Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Dedifferentiated Carcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "High-Dose-Rate Vaginal Cuff Brachytherapy", "type": "RADIATION" }, { "name": "Hyaluronidase-zzxf/Pertuzumab/Trastuzumab", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Trastuzumab/Hyaluronidase-oysk", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 360, "start_date": "2022-11-16", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-23T13:15:48.843Z", "location_count": 404, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 304 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05256225" }, { "nct_id": "NCT04092270", "title": "A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial High Grade Endometrioid Adenocarcinoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube High Grade Serous Adenocarcinoma", "Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma", "FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Undifferentiated Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian Low Grade Serous Adenocarcinoma", "Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor", "Recurrent Ovarian Mucinous Adenocarcinoma", "Recurrent Ovarian Transitional Cell Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Peposertib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 55, "start_date": "2020-05-07", "completion_date": "2027-06-08", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-07-23T13:15:48.843Z", "location_count": 11, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04092270" }, { "nct_id": "NCT00413322", "title": "Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor" ], "interventions": [ { "name": "belinostat", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Valerio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2005-09", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2015-07-08", "last_synced_at": "2026-07-23T13:15:48.843Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Portsmouth", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00413322" } ] }